ZELTIQ(R) Aesthetics Reaches 2,000,000th CoolSculpting Treatment Cycle Milestone

ZELTIQ® Aesthetics, Inc. ZLTQ, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it recently shipped its 2,000,000th CoolSculpting treatment cycle. "As demonstrated by the shipment of our 2,000,000th cycle, the physician and consumer communities have embraced CoolSculpting as a procedure that works and that continues to expand the overall aesthetic market since non-invasive fat reduction appeals to a much broader range of the population, including men," said Mark Foley, President and Chief Executive Officer of ZELTIQ. "We estimate that, on average, a patient receives approximately 4 cycles per treatment which would imply that we have treated roughly 500,000 patients to date. While the shipment of our 2,000,000th cycle is an incredible accomplishment for the company, our market research shows that 22 million people in US alone are interested in reducing fat noninvasively(1), which would suggest that we are still in the early stages of creating and growing the non-invasive fat reduction market. Again, we are very excited about this significant achievement in the history of the Company." The one and only CoolSculpting procedure was developed by Harvard scientists and is based on the proprietary science of Cryolipolysis®, a process demonstrating that when fat cells are exposed to extreme cold, they die and are eliminated naturally from the body. Fat cells treated and eliminated by the procedure are gone for good, and patients can expect long-lasting results. There are over 3,500 CoolSculpting systems placed in nearly 3,000 practices in over 70 countries around the world. Furthermore, 25% of North American CoolSculpting centers have more than one Coolsculpting system in the practice.